Publicado

2024-10-20

Net costs of breast cancer care in a health promotion entity of Colombia

Costos netos de la atención del cáncer de mama en una entidad promotora de salud en Colombia

Palabras clave:

Health Care Economics and Organizations, Costs and Cost Analysis, Health Care Costs, Direct Service Costs, Breast Neoplasms (en)
Economía y Organizaciones para la Atención en Salud, Costos y Análisis de Costo, Costos de la Atención en Salud, Costos Directos de Servicios, Neoplasias de la Mama (es)

Descargas

Autores/as

  • José Ricardo Urrego-Novoa Universidad de Ciencias Aplicadas y Ambientales U.D.C.A. - Programa de Química Farmacéutica - Bogotá D.C. - Colombia. | Universidad Nacional de Colombia - Bogotá Campus - Facultad de Ciencias - Departamento de Farmacia - Bogotá D.C. - Colombia. https://orcid.org/0000-0002-1496-6610
  • Ana Lucía Hincapié-Echeverry University of Cincinnati - James L. Winkle College of Pharmacy - Cincinnati - Ohio - Estados Unidos https://orcid.org/0000-0002-6142-1744
  • Jorge Augusto Díaz-Rojas Universidad Nacional de Colombia - Sede Bogotá - Facultad de Ciencias - Departamento de Farmacia - Bogotá D.C.- Colombia https://orcid.org/0000-0003-0875-4846

Introduction: The estimation of costs associated with cancer care is essential for the implementation of technologies, programs, and policies aimed at prevention and treatment.

Objective: To estimate the average annual net costs of breast cancer care for each phase of care and the average annual net cost per patient in each phase of care of patients under the contributory regime subscribed to a health promotion entity (EPS by its Spanish acronym) in Colombia.

Material and methods: Retrospective matched case-control study conducted using data from 4 278 patients served between January 1, 2010, and December 31, 2016, by an EPS with a presence throughout Colombia (713 cases with breast cancer and 3 565 controls). Net costs were estimated utilizing the net cost method and were expressed in constant 2023 US dollars for each phase of care (initial, continuing, and last year of life).

Results: The average annual net costs of breast cancer care for the initial, continuing, and last year of life phases were 24 431 719.80 USD, 27 325 443.38 USD, and 6 786 347.62 USD, respectively. The average annual net costs per patient for these same phases were 50 583.27 USD, 46 710.16 USD, and 147 529.30 USD, respectively.

Conclusion: The average annual net costs of breast cancer care were higher in the continuing phase, followed by the initial and last year of life phases. In turn, the average annual net cost per patient was higher in the last year of life phase, followed by the initial phase.

Introducción. La estimación de costos de atención es fundamental para implementar tecnologías, programas y políticas en prevención y atención del cáncer.

Objetivo. Estimar los costos netos anuales promedio de atención del cáncer de mama por fase de atención y el costo neto anual promedio por paciente en cada fase de atención en pacientes afiliados a una entidad promotora de salud - EPS (régimen contributivo) de Colombia.

Materiales y métodos. Estudio de casos y controles pareado retrospectivo realizado con datos de 4 278 pacientes atendidas entre enero 1 de 2010 y diciembre 31 de 2016 en una EPS con presencia en toda Colombia (713 casos con cáncer de mama y 3 565 controles). Los costos netos se estimaron utilizando el método de costo neto y fueron expresados en dólares americanos constantes 2023 para cada fase de atención (inicial, continua y último año de vida).

Resultados. Los costos netos anuales promedio de atención del cáncer de mama para las fases inicial, continua y último año de vida fueron 24 431 719.80 USD, 27 325 443.38 USD y 6 786 347.62 USD, respectivamente, y los costos netos anuales promedio por paciente para estas mismas fases fueron de 50 583.27 USD, 46 710.16 USD y 147 529.30 USD.

Conclusión. Los costos netos anuales promedio de la atención del cáncer de mama fueron más altos en la fase continua, seguida de las fases inicial y último año de vida. Por su parte, el costo neto anual promedio por paciente fue más alto en la fase último año de vida, seguida por la fase inicial.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Today [Internet]. Lyon, France: International Agency for Research on Cancer; 2024 [cited 2024 Mar 10]. Available from: https://bit.ly/40yOv8m.

2. Schneider PP, Ramaekers BL, Pouwels X, Geurts S, Ibragimova K, de Boer M, et al. Direct medical costs of advanced breast cancer treatment: A real-world study in the Southeast of The Netherlands. Value Health. 2021;24(5):668-75. https://doi.org/nn4s.

3. Montiel-Jarquín ÁJ, Santiago-Carrillo MA, García-Galicia A, López-Bernal CA, Miranda-Martínez MA, Loria-Castellanos J. Análisis del coste directo de la atención médica y quirúrgica del cáncer de mama. Estudio comparativo entre etapas temprana y tardía en tercer nivel de atención. Cir Cir. 2023;91(1):28-33. https://doi.org/nn4w.

4. Moreno JA, Muñoz-Galindo I, Guarín N, Díaz J, Arevalo H. Direct costs of health care for breast cancer, the case of a health manteinance organization in Colombia. Value in Health. 2015;18(3):A254. https://doi.org/f3g2x5.

5. Gamboa O, Buitrago LA, Lozano T, Dieleman S, Gamboa C, Guzmán EL, et al. Costos directos de la atención del cáncer de mama en Colombia. Rev Colomb Cancerol. 2016;20(2):52-60. https://doi.org/nn9t.

6. Torres GF, Alarcón BA, Reyes-Sanchez JM, Castaño-Gamboa N, Buitrago G. Net costs of breast cancer in Colombia: a cost-of-illness study based on administrative claims databases. Cost Eff Resour Alloc. 2024;22(1):54. https://doi.org/nn9w.

7. Gamboa O, Buitrago G, Patiño AF, Agudelo NR, Saldaña-Espinel L, Eslava-Schmalbach J, et al. Fragmentation of Care and Its Association With Survival and Costs for Patients With Breast Cancer in Colombiá. JCO Glob Oncol. 2023;9:e2200393. https://doi.org/gr9snj.

8. Lipscomb J, Yabroff KR, Brown ML, Lawrence W, Barnett PG. Health Care Costing: Data, Methods, Current Applications. Med Care. 2009;47(7 Suppl 1):S1-6. https://doi.org/dmhns2.

9. Barlow WE. Overview of Methods to Estimate the Medical Costs of Cancer. Med Care. 2009;47(7 Suppl 1):S33-6. https://doi.org/ccs8cn.

10. Francisci S, Capodaglio G, Gigli A, Mollica C, Guzzinati S. Cancer cost profiles: The Epicost estimation approach. Front Public Heal. 2022;10:974505. https://doi.org/npj4.

11. Blayney DW, Seto T, Hoang N, Lindquist C, Kurian AW. Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. JCO Oncol Pract. 2021;17(10):e1403-12. https://doi.org/npj8.

12. Bugge C, Brustugum OT, Seether EM, Kristiansen IS. Phase-and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study. Medicine (Baltimore). 2021;100(26):e26523. https://doi.org/ntc2.

13. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-41. https://doi.org/dkmdx2.

14. Urrego-Novoa JR. Estimación de los costos directos médicos netos de la atención de cáncer de mama en el Sistema General de Seguridad Social de Colombia [thesis on the Internet]. Bogotá D.C.: Universidad Nacional de Colombia; 2024 [cited 2024 Dec24]. Available from: https//repositorio.unal.edu.co/handle/unal/87242.

15. de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16(1):809. https://doi.org/f87vmm.

16. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, Ritzwoller DP, Fishman PA, Salloum RG, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Cancer Netw. 2018;16(4):402-10. https://doi.org/gdd2sk.

17. Iacus SM, King G, Porro G. cem : Software for Coarsened Exact Matching. J Stat Softw. 2009;30(9):1-27. https://doi.org/gjjx3g.

18. Iacus SM, King G, Porro G. Causal inference without balance checking: Coarsened exact matching. Political Analysis. 2012;20(1):1-24. https://doi.org/dppdx5.

19. Salud Total EPS-S. Informe de Gestión 2016 [Internet]. Bogotá D.C.: Salud Total EPS-S; 2017 [cited 2024 Nov 16]. Available from: https://bit.ly/4g0LvG7.

20. Organización Panamericana de la Salud (OPS). CIE-10. Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud. Volumen 1. Décima Revisión [Internet]. Ginebra: OPS; 2003 [cited 2024 Nov 6]. Available from: https://bit.ly/4asLidJ.

21. Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, et al. Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients. Med Care. 2009;47(7 Supplement 1):S56-63. https://doi.org/cndjph.

22. Yabroff KR, Mariotto A, Tangka F, Zhao J, Islami F, Sung H, et al. Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. JNCI J Natl Cancer Inst. 2021;113(12):1670-82. https://doi.org/nq5n.

23. Yabroff KR, Mariotto A, Tangka F, Zhao J, Islami F, Sung H, et al. Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. J Natl Cancer Inst. 2021;113(12):1670-82. https://doi.org/nq5n.

24. R. Core Team. R: The R Project for Statistical Computing [Software]. 2016 [cited 2024 Sep 21]. Available from: https://www.r-project.org/.

25. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol. 2007;4(11):643-56. https://doi.org/bvz8nf.

26. Park J, Look KA. Health care expenditure burden of cancer care in the United States. Inqiry. 2019;56:46958019880696. https://doi.org/gncgwg.

27. Lao C, Mondal M, Kuper-Hommel M, Campbell I, Lawrenson R. Differences in breast cancer costs by cancer stage and biomarker subtype in New Zealand. Pharmacoecono Open. 2022;6(4):539-48. https://doi.org/nq5p.

28. Colombia. Departamento Administrativo Nacional de Estadística (DANE). Índice de Precios al Consumidor [Internet]. Bogotá D.C.: DANE; 2024 [cited 2024 Sep 21]. Available from: https://bit.ly/3PH3xmd.

29. Sabermahani A, Sirizi MJ, Zolala F, Nazari S. Out-of-Pocket Costs and Importance of Nonmedical and Indirect Costs of Inpatients. Value Health Reg Issues. 2021;24:141-7. https://doi.org/nq5q.

30. Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022;14(10): 2569. https://doi.org/gsdqkk.

31. Luo C, Wang L, Zhang Y, Lu M, Lu B, Cai J, et al. Advances in breast cancer screening modalities and status of global screening programs. Chronic Dis Transl Med. 2022;8(2):112-23. https://doi.org/nqbk.

32. Hall LH, King NV, Graham CD, Green SMC, Barber A, Neal RD, et al. Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines. J Cancer Surviv. 2022;16(6):1296-338. https://doi.org/gqhqfz

33. Figueiredo FWDS, Almeida TCDC, Cardial DT, Maciel EDS, Fonseca FLA, Adami F. The role of health policy in the burden of breast cancer in Brazil. BMC Womens Health. 2017;17(1):121. https://doi.org/ghd86h.

34. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/gtp98r.

35. Trogdon JG, Ekwueme DU, Poehler D, Thomas CC, Reeder-Hayes K, Allaire BT. Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis. Breast Cancer Res Treat. 2017;166(1):207-15. https://doi.org/gcgn7c.

36. Trogdon JG, Baggett CD, Gogate A, Reeder-Hayes KE, Rotter J, Zhou XI, et al. Medical costs associated with metastatic breast cancer in younger, midlife, and older women. Breast Cancer Res Treat. 2020;181(3):653-65. https://doi.org/nq5r.

37. Hu L, Li L, Ji J, Sanderson M. Identifying and understanding determinants of high healthcare costs for breast cancer: a quantile regression machine learning approach. BMC Health Serv Res. 2020;20(1):1066. https://doi.org/gnwmvg.

38. Fondo Colombiano de Enfermedades de Alto Costo C de AC (CAC). Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2023. Bogotá D.C.: CAC; 2024.

39. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524-41. https://doi.org/gqxgp5.

40. Xu H, Xu B. Breast cancer: Epidemiology, risk factors and screening. Chinese J Cancer Res. 2023;35(6):565-83. https://doi.org/nqw3.

41. Omer AAA, Bin Dayel SA, Hummedi ASA, Almuhaimed NIA. The epidemiological and clinicopathological features of breast cancer in Riyadh, Saudi Arabia. Saudi Med J. 2024;45(3):288-94. https://doi.org/nq3g.

42. Duarte C, Salazar A, Strasser-Weippl K, de Vries E, Wiesner C, Arango-Gutiérrez A, et al. Breast cancer in Colombia: a growing challenge for the healthcare system. Breast Cancer Res Treat. 2021;186(1):15-24. https://doi.org/gh4mbx.

43. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15-23. https://doi.org/gsb5hn.

44. Mariotto AB, Enewold L, Zhao J, Zeruto CA, Robin Yabroff K. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304-12. https://doi.org/gnwmss.

45. Sun L, Legood R, Dos-Santos-Silva I, Gaiha SM, Sadique Z. Global treatment costs of breast cancer by stage: A systematic review. PLoS One. 2018;13(11):e0207993. https://doi.org/gfpr8t.

46. Colombia. Dirección de Regulación de la Operación del Aseguramiento en Salud, Riesgos Laborales y Pensiones. Boletín del aseguramiento en salud. Boletín No. 01 - Primer trimestre 2017. Bogotá D.C.: Ministerio de Salud y protección social; 2017.

Licencia

Derechos de autor 2024 Revista de la Facultad de Medicina

Creative Commons License

Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.

-